Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05592626 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05592626 · ClinicalTrials.gov record · last posted 2026-08-11

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Study acronym: START-001
StatusRecruiting
PhasePhase 1/2
Started2023-01-04
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

Protocol amendment history 3 changes detected by DataLookout

2026-08-12
Trial sites reduced: 32 → 19 locations
2026-08-12
Primary completion pushed: 2026-10 → 2027-09
2026-08-12
Completion pushed: 2026-10 → 2027-09
Trial Details
NCT Number NCT05592626
Lead Sponsor Marengo Therapeutics, Inc.
Conditions Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma +6 more
Enrollment 366 participants
Start Date 2023-01-04
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-11